Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2015.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol
July 2020
Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Electronic address:
During the past recent years, various therapies emerged in the era of breast cancer. Breast cancer is a heterogeneous disease in which genetic and environmental factors are involved. Breast cancer stem cells (BCSCs) are the main player in the aggressiveness of different tumors and also, these cells are the main challenge in cancer treatment.
View Article and Find Full Text PDFPrognostic and predictive biomarkers in breast cancer: Past, present and future.
Semin Cancer Biol
October 2018
UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin and UCD School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland.
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint.
View Article and Find Full Text PDFClinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Eur J Cancer
April 2017
Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal.
Biomarkers play an essential role in the management of patients with invasive breast cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen receptors (ERs) and progesterone receptors (PRs) should be measured on all newly diagnosed invasive breast cancers. On the other hand, for selecting likely response to all forms of anti-HER2 therapy (trastuzumab, pertuzumab, lapatinib or ado-trastuzumab emtansine), determination of HER2 expression or gene copy number is mandatory.
View Article and Find Full Text PDFValidated biomarkers: The key to precision treatment in patients with breast cancer.
Breast
October 2016
UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; Medical Oncology Department, St Vincent's University Hospital, Dublin 4, Ireland.
Recent DNA sequencing and gene expression studies have shown that at a molecular level, almost every case of breast cancer is unique and different from other breast cancers. For optimum management therefore, every patient should receive treatment that is guided by the molecular composition of their tumor, i.e.
View Article and Find Full Text PDFBiomarkers in Breast Cancer: Where Are We and Where Are We Going?
Adv Clin Chem
April 2016
Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.
Biomarkers play an important role in the detection and management of patients with breast cancer. Thus, BRCA1/2 mutation testing is used for risk assessment in families with a high prevalence of breast and ovarian cancer. Following a diagnosis of breast cancer, measurement of multi-analyte profiles such as uPA/PAI-1 or Oncotype DX may be used for determining prognosis and identifying lymph node-negative patients who may be spared from having to receive adjuvant chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!